OHR Pharma Offers Positive Interim Top-Line Clinical Data from Phase II Study of Squalamine Eye Drops in Patients with WetAMD

By: via Benzinga
Ohr Pharmaceutical, Inc. (Nasdaq: OHRP), an ophthalmology research and development company, today announced positive top-line interim ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.